Prosecution Insights
Prosecution Insights
Tech Center 6200 • Art Units: 1632 1637 1645 6221
This examiner grants 47% of resolved cases
Alexandra Rose Lippolis serves in Tech Center 6200 and Art Unit 1632. The examiner has 32 resolved cases. The allowance rate is 46.9 percent. This rate indicates that fewer than half of the applications reaching a final disposition are granted. With 32 resolved cases, practitioners should be aware that the data set is smaller than that of more veteran examiners.
The median days to allowance is 1431. This is a relatively long timeframe for reaching a successful conclusion in prosecution. The interview lift is 59.0 percent. This is an exceptionally high lift, representing a massive increase in the probability of allowance when an interview is held. Compared to the 46.9 percent allowance rate, the 59.0 percent lift suggests that interviews are a transformative tool for this examiner.
For those in Art Unit 1632, the 59.0 percent interview lift is the most critical metric in the profile. The 1431 median days to allowance indicates that prosecution may be lengthy. However, the 46.9 percent allowance rate can be significantly improved through direct engagement. The data suggests that oral advocacy is essential for overcoming the challenges of the baseline examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18456037 | MODIFIED CYANOBACTERIUM, MODIFIED CYANOBACTERIUM PRODUCTION METHOD, AND PROTEIN PRODUCTION METHOD | Final Rejection | Panasonic Intellectual Property Management Co., Ltd. |
| 17748617 | MODIFIED CYANOBACTERIUM, MODIFIED CYANOBACTERIUM PRODUCTION METHOD, AND PROTEIN PRODUCTION METHOD | Non-Final OA | Panasonic Intellectual Property Management Co., Ltd. |
| 18568796 | IMPROVED CYTOSINE TO GUANINE BASE EDITORS | Non-Final OA | Massachusetts Institute of Technology |
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17776269 | SMALL TYPE II CAS PROTEINS AND METHODS OF USE THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17422490 | SYSTEMS AND METHODS FOR CULTURING CELLS IN SUSPENSION | Non-Final OA | CORNING INCORPORATED |
| 17913723 | LINKED DNA PRODUCTION METHOD AND VECTOR COMBINATION FOR USE THEREIN | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 17733265 | DNA CAPTURE-BASED GRAVITATIONAL FLOW-THROUGH ASSAY FOR ANTIGEN DETECTION | Non-Final OA | University of South Florida |
| 18025446 | TARGETED DEAMINASE AND BASE EDITING USING SAME | Final Rejection | INSTITUTE FOR BASIC SCIENCE |
| 18415949 | INTEIN TECHNOLOGY TO DELIVER ABCA3 LIPID TRANSPORTER FOR ABCA3 DEFICIENCY | Non-Final OA | Children's Hospital Medical Center |
| 18264885 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) AND OTHER DISORDERS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18180718 | SYSTEMS AND METHODS FOR GENOME-WIDE ANNOTATION OF GENE REGULATORY ELEMENTS LINKED TO CELL FITNESS | Final Rejection | Duke University |
| 17759564 | CELL SPECIFIC, SELF-INACTIVATING GENOMIC EDITING USING CRISPR-CAS SYSTEMS HAVING RNASE AND DNASE ACTIVITY | Final Rejection | Icahn School of Medicine at Mount Sinai |
| 17602204 | HYBRID NUCLEIC ACID SWITCHES | Final Rejection | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18293091 | SMALL MOLECULE AND SIRNA INHIBITORS AGAINST LIPOCALIN-2 | Non-Final OA | UNIVERSITY OF PUERTO RICO |
| 18268251 | NUCLEIC ACID CONSTRUCT FOR AIDS GENE THERAPY | Non-Final OA | KANGLIN BIOTECH (HANGZHOU) CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy